$37.20
8.19% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$40.52
-2.37 5.53% 1M
-15.19 27.27% 6M
-6.52 13.86% YTD
-30.40 42.87% 1Y
+0.48 1.20% 3Y
+28.56 238.80% 5Y
+33.50 477.21% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
+0.27 0.67%
ISIN
US23282W6057
Symbol
CYTK
Sector
Industry

Key metrics

Market capitalization $4.80b
Enterprise Value $4.51b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 244.20
P/S ratio (TTM) P/S ratio 259.77
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 145.34%
Revenue (TTM) Revenue $18.47m
EBIT (operating result TTM) EBIT $-536.25m
Free Cash Flow (TTM) Free Cash Flow $-399.80m
Cash position $1.08b
EPS (TTM) EPS $-5.28
P/E forward negative
P/S forward 122.65
EV/Sales forward 115.30
Short interest 18.29%
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Cytokinetics, Incorporated forecast:

19x Buy
86%
3x Hold
14%

Analyst Opinions

22 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
86%
Hold
14%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
18 18
145% 145%
100%
- Direct Costs 9.53 9.53
31% 31%
52%
8.94 8.94
243% 243%
48%
- Selling and Administrative Expenses 206 206
29% 29%
1,114%
- Research and Development Expense 330 330
4% 4%
1,786%
-527 -527
9% 9%
-2,852%
- Depreciation and Amortization 9.53 9.53
31% 31%
52%
EBIT (Operating Income) EBIT -536 -536
8% 8%
-2,903%
Net Profit -590 -590
12% 12%
-3,192%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Positive
Investors Business Daily
2 days ago
Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
4 days ago
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 2:15 PM Eastern Time.
Neutral
GlobeNewsWire
15 days ago
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) --  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and Health Outcomes in HCM), an online, open access, interactive public health educat...
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 498
Founded 1997
Website www.cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today